Peregrine Asset Advisers Inc. lessened its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 21.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,596 shares of the company’s stock after selling 2,030 shares during the quarter. Eli Lilly and Company makes up about 2.7% of Peregrine Asset Advisers Inc.’s holdings, making the stock its 5th largest position. Peregrine Asset Advisers Inc.’s holdings in Eli Lilly and Company were worth $6,877,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently modified their holdings of LLY. Tidemark LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $29,000. Core Wealth Advisors Inc. boosted its position in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the last quarter. Lynx Investment Advisory bought a new position in Eli Lilly and Company in the 2nd quarter valued at $32,000. LGT Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $36,000. Finally, Frank Rimerman Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth $37,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Insider Activity
In related news, major shareholder Lilly Endowment Inc sold 1,441 shares of Eli Lilly and Company stock in a transaction on Friday, June 28th. The shares were sold at an average price of $915.02, for a total value of $1,318,543.82. Following the transaction, the insider now owns 97,367,369 shares in the company, valued at approximately $89,093,089,982.38. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 451,900 shares of company stock valued at $418,732,178. Corporate insiders own 0.13% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Report on Eli Lilly and Company
Eli Lilly and Company Stock Performance
NYSE LLY opened at $924.05 on Tuesday. The company’s 50 day simple moving average is $897.24 and its two-hundred day simple moving average is $835.09. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53. The stock has a market capitalization of $878.22 billion, a PE ratio of 136.09, a P/E/G ratio of 2.79 and a beta of 0.42.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were issued a $1.30 dividend. The ex-dividend date was Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.56%. Eli Lilly and Company’s payout ratio is 76.58%.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Recommended Stories
- Five stocks we like better than Eli Lilly and Company
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Why Zillow Group Could Soar with the Upcoming Interest Rate Cuts
- High Flyers: 3 Natural Gas Stocks for March 2022
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- How to Calculate Options Profits
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.